TradeFlare's AI research teams analysed ZYME on 5 market nights between April 14, 2026 and October 1, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 1, 2026 | BUY | $26.49 | $30.46 / $22.52 | -2.7% | not yet | The fundamental and sentiment catalysts are likely to play out over this timeframe. |
| June 30, 2026 | BUY | $24.10 | — / — | +1.9% | -15.8% | Workforce reduction signals potential cost discipline and margin expansion. |
| May 6, 2026 | BUY | $26.68 | — / — | -11.0% | -9.1% | Positive clinical trial data for pipeline assets. |
| May 5, 2026 | HOLD | $26.78 | — / — | -10.4% | -8.7% | Positive clinical trial results for key drug candidates. |
| April 14, 2026 | BUY | $26.17 | $40.00 / $24.68 | +4.8% | -11.4% | The fundamental analysis suggests a medium-term investment horizon to allow for the pipeline to develop and the royalty-driven business model to mature. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.